• Design Therapeutics began dosing patients in a Phase 1 multiple-ascending dose trial of DT-818 in adults with myotonic dystrophy type-1.
• The study will assess safety, tolerability, pharmacokinetics, pharmacodynamic effects; results will be reported in 2027.
• DT-818 aims to reduce transcription of the mutant DMPK allele, targeting the disease’s underlying genetic driver.
• The start of patient dosing advances DT-818 into clinical testing, a key step toward establishing early clinical proof of concept.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED9754562) on June 30, 2026, and is solely responsible for the information contained therein.